Neuropathic Pain Market Opportunities and Market Segmentation Insights: 2024 to 2030

The global neuropathic pain market, valued at USD 8.13 billion in 2023, is projected to reach USD 11.91 billion by 2030, growing at a CAGR of 5.6%. The rise in chronic diseases such as diabetes, multiple sclerosis, and neurological conditions continues to fuel the market growth. Additionally, the increasing focus on advanced pharmacological and non-pharmacological treatments, including novel drug therapies, is expected to drive demand across global markets.

𝐆𝐞𝐭 𝐚 𝐜𝐥𝐨𝐬𝐞𝐫 𝐥𝐨𝐨𝐤 𝐚𝐭 𝐭𝐡𝐞 𝐠𝐚𝐦𝐞-𝐜𝐡𝐚𝐧𝐠𝐢𝐧𝐠 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐬 𝐝𝐫𝐢𝐯𝐢𝐧𝐠 𝐬𝐮𝐜𝐜𝐞𝐬𝐬 :https://www.maximizemarketresearch.com/request-sample/34992/

𝐂𝐨𝐮𝐧𝐭𝐫𝐲-𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

𝐍𝐞𝐮𝐫𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐚𝐢𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐫𝐨𝐰𝐭𝐡 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐢𝐧 𝐕𝐢𝐞𝐭𝐧𝐚𝐦

Vietnam is seeing a rise in chronic conditions like diabetes, which has led to an increased need for neuropathic pain treatments. 𝐏𝐟𝐢𝐳𝐞𝐫 and 𝐁𝐚𝐲𝐞𝐫 are looking to expand their presence in the region, offering advanced treatments for neuropathic pain management.

𝐍𝐞𝐮𝐫𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐚𝐢𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬 𝐢𝐧 𝐓𝐡𝐚𝐢𝐥𝐚𝐧𝐝

Thailand's growing elderly population is driving the demand for neuropathic pain solutions. With increasing awareness and healthcare investment, the market is expected to continue evolving, with more companies like 𝐍𝐨𝐯𝐚𝐫𝐭𝐢𝐬 focusing on localizing treatment options to meet the needs of the population.

𝐍𝐞𝐮𝐫𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐚𝐢𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐢𝐧 𝐉𝐚𝐩𝐚𝐧

Japan has one of the world's highest elderly populations, contributing to a significant demand for neuropathic pain therapies. Recent mergers, such as 𝐓𝐚𝐤𝐞𝐝𝐚 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥'𝐬 acquisition of 𝐓𝐢𝐆𝐞𝐧𝐢𝐱, highlight the country's increasing focus on pain management solutions tailored to the elderly.

𝐔𝐧𝐥𝐨𝐜𝐤 𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐛𝐲 𝐞𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐬𝐚𝐦𝐩𝐥𝐞 𝐯𝐢𝐚 𝐭𝐡𝐞 𝐥𝐢𝐧𝐤 @https://www.maximizemarketresearch.com/request-sample/34992/

𝐍𝐞𝐮𝐫𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐚𝐢𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐂𝐨𝐧𝐬𝐨𝐥𝐢𝐝𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐂𝐡𝐢𝐧𝐚

China's growing healthcare market has seen consolidation, as major players like 𝐇𝐢𝐤𝐦𝐚 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 and 𝐂𝐢𝐩𝐥𝐚 enter the competitive field of neuropathic pain treatment. The government's push for more comprehensive healthcare coverage is expected to propel market growth further.

𝐍𝐞𝐮𝐫𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐚𝐢𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐔𝐩𝐝𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐒𝐨𝐮𝐭𝐡 𝐊𝐨𝐫𝐞𝐚

With a fast-growing elderly population and a focus on healthcare innovation, South Korea is seeing rising demand for advanced neuropathic pain management. The country is benefiting from more investment in R&D for novel therapies and increased government spending on healthcare infrastructure.

𝐍𝐞𝐮𝐫𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐚𝐢𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐫𝐨𝐰𝐭𝐡 𝐢𝐧 𝐒𝐢𝐧𝐠𝐚𝐩𝐨𝐫𝐞

Singapore's growing role as a regional healthcare hub, coupled with its advanced research and clinical trial activities, is driving the demand for new treatments. The government is supporting the development of more effective pain management solutions to cater to the growing elderly population.

𝐍𝐞𝐮𝐫𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐚𝐢𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐔𝐧𝐢𝐭𝐞𝐝 𝐒𝐭𝐚𝐭𝐞𝐬

The U.S. remains the largest market for neuropathic pain treatments, with the increasing incidence of chronic pain driving demand. The country is seeing significant shifts toward non-opioid therapies and the development of new drugs to address the opioid crisis, with major companies such as 𝐉𝐨𝐡𝐧𝐬𝐨𝐧 & 𝐉𝐨𝐡𝐧𝐬𝐨𝐧 investing heavily in R&D.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐝𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐝𝐚𝐭𝐚 𝐚𝐧𝐝 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐛𝐲 𝐯𝐢𝐞𝐰𝐢𝐧𝐠 𝐭𝐡𝐞 𝐬𝐚𝐦𝐩𝐥𝐞 @https://www.maximizemarketresearch.com/request-sample/34992/

𝐍𝐞𝐮𝐫𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐚𝐢𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐲 𝐢𝐧 𝐄𝐮𝐫𝐨𝐩𝐞

Europe's aging population and increasing chronic disease prevalence are driving demand for innovative neuropathic pain treatments. The region also benefits from advancements in pain relief technologies, with companies like 𝐄𝐥𝐢 𝐋𝐢𝐥𝐥𝐲 and 𝐍𝐨𝐯𝐚𝐫𝐭𝐢𝐬 investing in the development of next-generation pain relief therapies.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧:

𝐛𝐲 𝐃𝐫𝐮𝐠 𝐂𝐥𝐚𝐬𝐬

Antidepressants
Anticonvulsant
Opioids
Capsaicin
Others

The market is divided into categories such as capsaicin, opioids, antidepressants, anticonvulsants, and others. The market for neuropathic pain was dominated by the anticonvulsant segment in 2023 and is anticipated to continue to do so during the forecast period. The anticonvulsant section of the neuropathic pain market consists of a class of drugs that are mainly given to treat epilepsy, or seizures, but are also frequently used to treat neuropathic pain. Anticonvulsants, sometimes referred to as antiepileptic medications (AEDs), work by adjusting the central nervous system's neurotransmitter activity and neuronal excitability.

𝐛𝐲 𝐈𝐧𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧

Diabetic Neuropathy
Spinal Stenosis
Chemotherapy-Induced Peripheral Neuropathy
Others

Diabetic neuropathy, spinal stenosis, chemotherapy-induced peripheral neuropathy, and others are the market segments. The market for neuropathic pain was dominated by the diabetic neuropathy category in 2023 and is anticipated to continue to do so during the forecast period. Within the larger neuropathic pain market, diabetic neuropathy is a subset that focuses on neuropathic pain disorders that develop as a result of diabetes mellitus. In people with diabetes, diabetic neuropathy is the term used to describe nerve damage brought on by extended exposure to elevated blood sugar levels (hyperglycemia). Sensory abnormalities and neuropathic pain are indications of nerve injury that can appear in different regions of the body.

𝐛𝐲 𝐃𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐂𝐡𝐚𝐧𝐧𝐞𝐥

Hospital Pharmacies
Drugs Stores and Retail Pharmacies
Online Pharmacies

𝐆𝐞𝐭 𝐚 𝐝𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬:https://www.maximizemarketresearch.com/market-report/global-neuropathic-pain-market/34992/

𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:

𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚:
1. Pfizer Inc. - New York, United States
2. Eli Lilly and Company - Indianapolis, United States
3. Johnson & Johnson - New Brunswick, United States
4. Teva Pharmaceutical Industries Ltd. - Tel Aviv, Israel
5. Purdue Pharma - Stamford, United States
6. Endo Pharmaceuticals Inc. - Dublin, Ireland
7. AbbVie Inc. - North Chicago, United States
8. Mallinckrodt Pharmaceuticals - Staines-upon-Thames, United Kingdom
9. Biogen Inc. - Cambridge, United States

𝐄𝐮𝐫𝐨𝐩𝐞:
10. GlaxoSmithKline plc - Brentford, United Kingdom
11. Novartis AG - Basel, Switzerland
12. AstraZeneca plc - Cambridge, United Kingdom
13. Bayer AG - Leverkusen, Germany
14. Merck KGaA - Darmstadt, Germany
15. Boehringer Ingelheim - Ingelheim am Rhein, Germany
16. Sanofi - Paris, France
17. UCB S.A. - Brussels, Belgium
18. Ipsen Pharma - Paris, France
19. Grünenthal GmbH - Aachen, Germany

𝐀𝐬𝐢𝐚 𝐏𝐚𝐜𝐢𝐟𝐢𝐜:
20. Takeda Pharmaceutical Company Limited - Tokyo, Japan
21. Eisai Co., Ltd. - Tokyo, Japan
22. Astellas Pharma Inc. - Tokyo, Japan
23. Otsuka Holdings Co., Ltd. - Tokyo, Japan
24. Mitsubishi Tanabe Pharma Corporation - Osaka, Japan

𝐂𝐡𝐞𝐜𝐤 𝐨𝐮𝐭 𝐨𝐮𝐫 𝐭𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐬𝐭𝐮𝐝𝐢𝐞𝐬 𝐭𝐨 𝐮𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐬𝐡𝐢𝐟𝐭𝐬 :

♦ Global Smoked Fish Market https://www.maximizemarketresearch.com/market-report/global-smoked-fish-market/147525/

♦ Irish Whiskey Market https://www.maximizemarketresearch.com/market-report/global-irish-whiskey-market/94141/

♦ India lithium-ion battery market https://www.maximizemarketresearch.com/market-report/india-lithium-ion-battery-market/29994/

♦ Walnut Market https://www.maximizemarketresearch.com/market-report/global-walnut-market/24016/

♦ Saccharin Market https://www.maximizemarketresearch.com/market-report/saccharin-market/188060/

♦ Starch Market https://www.maximizemarketresearch.com/market-report/global-starch-market/112948/

♦ Hose Reel Market https://www.maximizemarketresearch.com/market-report/hose-reel-market/78645/

♦ Corundum Market https://www.maximizemarketresearch.com/market-report/corundum-market/148451/

♦ Global Cesium Market https://www.maximizemarketresearch.com/market-report/global-cesium-market/89395/

♦ Global Automotive Electric Oil Pump Market https://www.maximizemarketresearch.com/market-report/global-automotive-electric-oil-pump-market/35711/

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬:

MAXIMIZE MARKET RESEARCH PVT. LTD.
3rd Floor, Navale IT park Phase 2,
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India.
+91 9607365656
sales@maximizemarketresearch.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Maximize Market Research is one of the fastest-growing market research and business consulting firms serving clients globally. Our revenue impact and focused growth-driven research initiatives make us a proud partner of majority of the Fortune 500 companies. We have a diversified portfolio and serve a variety of industries such as IT & telecom, chemical, food & beverage, aerospace & defense, healthcare and others.

This release was published on openPR.